Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Extension in Active Lupus Nephritis
NCT05232864Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of secukinumab in lupus nephritis (LN), sponsored by Novartis. Started Aug 2022; status: terminated.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05232864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232864.